Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
Globe Newswire•24/08/2026•08:00 ET
0
Whiz Insights
-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan --
-- Commercial launch in Japan expected by end of 2026, pending final pricing determination --
Get started
Create a free account to read the full story.